Oncoclínicas planning to expand partnership with Hapvida nationwide
Oncoclínicas projeta ampliação nacional da parceria com Hapvida
Intel ID : 413053
|
||||
Relevant Documents
| Notice / Relevant Fact | 01 Apr 2025 | Oncoclinica_Comunicado_Colaboracao_Hapvida_2025.pdf | PT |
|
| Intel ID | 413053 | |
| Value | ND | |
| Native Currency |
Brazilian Real (BRL)
Exchange Rate:  |
|
|
Financial Data - Oncoclínicas
(31 Dec 2023) |
Revenue: EUR 1.023,22m EBITDA: EUR 189,29m Net Debt: EUR 630,42m Exchange Rate:
|
|
| Date |
 |
|
| Country | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
30.05.11 Oncology (Primary) 30 Healthcare / 30.05 Specialized Medicine 25.02.04 Life & Health Insurance (Primary) 25 Financial Services / 25.02 Insurance |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.02.04 Life & Health Insurance 25 Financial Services / 25.02 Insurance |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.05.11 Oncology 30 Healthcare / 30.05 Specialized Medicine |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.